Newsroom

Patient Navigation in Immuno-Oncology


(AJMC.org) BEING DIAGNOSED WITH CANCER is often the scariest news a patient will hear in his or her lifetime. In addition to the physical toll of the disease itself, there are numerous other factors associated ...

Cooling Down ICER? Five Questions to Consider


(ACCCBuzz) Jan 25, 2017 – Although the value-based reimbursement train has definitely left the station and is picking up speed, those in the oncology community continue to grapple with the thorny ...

First Opinion: Who Will Pay For CRISPR?


(STAT) June 26, 2017 - The ruckus over the CRISPR gene-editing system hides a dark reality: its high cost may make it unaffordable and questions remain whether most insurance companies will pay for it....

Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial


(BMS) June 24, 2017 - Combination therapy demonstrated a sustained reduction in risk of progression/death of 29% and relative improvement of 50% in progression-free survival rate of ELd (21%) compared to Ld alone (14%); the extended follow-up data is the longest of an Immuno-Oncology agent in relapsed/refractory multiple myeloma; the data...

No Survival Benefit With Up-front Nivolumab in Lung Cancer


(Medscape Medical News) June 21, 2017 - The programmed death 1 (PD-1) immune-checkpoint-inhibitor-antibody nivolumab (Opdivo, Bristol-Myers Squibb) did not yield longer progression-free survival (PFS) than platinum-based chemotherapy when used as a first-line therapy in patients with untreated stage IV or recurrent non–small cell lung c...

Merck KGaA Ventures Forms New Immuno-Oncology Company IOnctura


(RTTNews.com) June 20, 2017 - Merck KGaA announced its corporate venture arm Merck Ventures created iOnctura SA, Geneva, Switzerland. This immuno-oncology spin-out company was formed around two assets from the Healthcare R&D portfolio of Merck and three assets from Cancer Research Technology or CRT....

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer


(eFFECTOR Therapeutics) June 20, 2017 – eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany, to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC). ...